C4 Therapeutics (CCCC) Expected to Announce Quarterly Earnings on Thursday

Key Points

• C4 Therapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting losses of ($0.41) per share and revenue of $5.24 million.
• The company reported a negative return on equity of 45.86% and a negative net margin of 259.60% in its last quarterly earnings.
• Institutional investors hold 78.81% of C4 Therapeutics' stock, with AQR Capital Management increasing its stake by 957.6% in the first quarter.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $5.24 million for the quarter.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative net margin of 259.60% and a negative return on equity of 45.86%. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $3.54 million. On average, analysts expect C4 Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

C4 Therapeutics Stock Up 3.4%

Shares of CCCC traded up $0.07 during trading on Friday, reaching $2.12. 750,601 shares of the company traded hands, compared to its average volume of 1,529,366. C4 Therapeutics has a twelve month low of $1.09 and a twelve month high of $7.22. The stock has a market cap of $150.54 million, a PE ratio of -1.44 and a beta of 2.97. The stock has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $2.06.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in C4 Therapeutics by 957.6% during the 1st quarter. AQR Capital Management LLC now owns 140,532 shares of the company's stock worth $225,000 after acquiring an additional 127,244 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in C4 Therapeutics by 8.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company's stock worth $996,000 after acquiring an additional 49,065 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in C4 Therapeutics during the 1st quarter worth approximately $43,000. Institutional investors and hedge funds own 78.81% of the company's stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.